Guide — Pharmacology
Cardiac Medications Overview
Cardiac medications are among the most frequently administered drugs in nursing practice. From heart failure to hypertension to arrhythmia management, understanding drug class mechanisms, indications, side effects, and nursing monitoring requirements is essential for safe patient care and NCLEX success.
11 min read · Pharmacology
Educational use only. Cardiac medication dosing, titration, and hold parameters are individualized and provider-ordered. Always verify orders, check vital signs before administration, and follow your facility's protocols. This material supports nursing education and exam review. It is not medical advice and is not a substitute for clinical judgment, institutional policy, or medical direction. Always follow facility protocols and current provider orders.
Overview
Cardiac medications target multiple pathophysiological mechanisms — neurohormonal activation in heart failure, arterial stiffness in hypertension, ischemia in coronary artery disease, and abnormal electrical conduction in arrhythmias. Most patients with cardiac conditions take multiple drug classes, each targeting a different mechanism.
The nurse's role includes: verifying pre-administration vital signs, knowing hold parameters, recognizing adverse effects, monitoring laboratory values, and educating patients on adherence and safety.
Key Drug Classes
ACE Inhibitors (-pril)
Examples: Lisinopril, enalapril, captopril, ramipril
Mechanism: Block conversion of angiotensin I → angiotensin II → vasodilation, reduced aldosterone, decreased BP and afterload
Uses: Hypertension, heart failure (HFrEF), post-MI, diabetic nephropathy
Key side effects: Dry persistent cough (bradykinin accumulation — most common reason for discontinuation), hyperkalemia, hypotension (first dose), angioedema (rare but life-threatening — check for tongue/throat swelling)
Nursing monitoring: BP before administration, potassium levels, BUN/creatinine; hold for SBP < 90 per protocol; contraindicated in pregnancy
Angiotensin Receptor Blockers (ARBs) (-sartan)
Examples: Losartan, valsartan, candesartan, olmesartan
Mechanism: Block angiotensin II at AT₁ receptors → vasodilation, decreased BP and afterload. Do not affect bradykinin (no cough).
Uses: Hypertension, heart failure (alternative to ACE inhibitor), diabetic nephropathy, post-MI
Key side effects: Hyperkalemia, hypotension, dizziness. No ACE inhibitor cough. Angioedema possible (rare). Contraindicated in pregnancy.
Nursing monitoring: BP, potassium, renal function. Do not combine with ACE inhibitors (dual RAAS blockade increases adverse effects).
ARNIs — Angiotensin Receptor-Neprilysin Inhibitors
Example: Sacubitril/valsartan (Entresto)
Mechanism: Combines ARB (valsartan) + neprilysin inhibitor (sacubitril). Neprilysin inhibition increases natriuretic peptides → vasodilation, natriuresis, reduced cardiac remodeling.
Uses: Chronic HFrEF (EF ≤ 40%) — reduces mortality and hospitalization. First-line in eligible HF patients.
Key side effects: Hypotension, hyperkalemia, renal impairment, angioedema (higher risk than ARB alone due to bradykinin effects from neprilysin inhibition). Must stop ACE inhibitor 36 hours before starting.
Nursing monitoring: BP, potassium, creatinine. Educate patient not to take with ACE inhibitor.
Beta-Blockers (-olol)
Examples: Metoprolol, carvedilol, atenolol, bisoprolol
Mechanism: Block β₁ (cardiac) and/or β₂ (bronchial/vascular) adrenergic receptors → decrease HR, BP, and contractility; reduce myocardial oxygen demand
Uses: Hypertension, heart failure (HFrEF — carvedilol, metoprolol succinate, bisoprolol), angina, post-MI, arrhythmias (rate control in atrial fibrillation)
Key side effects: Bradycardia, hypotension, fatigue, cold extremities, bronchospasm (use cardioselective agents cautiously in asthma/COPD), sexual dysfunction, masking of hypoglycemia symptoms
Nursing monitoring: Hold for HR < 60 or SBP < 90 (per protocol). Never abruptly discontinue — risk of rebound hypertension and angina.
Calcium Channel Blockers (CCBs)
Types:
Dihydropyridines (-dipine): Amlodipine, nifedipine, felodipine
Primarily vascular — vasodilation, BP reduction. Minimal cardiac rate effect. Used for hypertension, angina.
Non-dihydropyridines: Diltiazem, verapamil
Cardiac and vascular — slow HR and AV conduction + vasodilation. Used for arrhythmias (rate control in AF/flutter), angina, hypertension.
Key side effects: Dihydropyridines: peripheral edema, flushing, headache, reflex tachycardia. Non-dihydropyridines: bradycardia, AV block, constipation (verapamil).
Nursing monitoring: BP, HR. Do not use non-dihydropyridines with beta-blockers in HF (additive negative chronotropy). Check grapefruit juice interaction with some CCBs.
Nitrates
Examples: Nitroglycerin (sublingual, IV, patch, ointment), isosorbide mononitrate, isosorbide dinitrate
Mechanism: Release nitric oxide → venous vasodilation (primarily) → decreased preload → reduced myocardial oxygen demand
Uses: Angina (acute relief and prevention), acute heart failure/pulmonary edema, hypertensive urgency
Key side effects: Headache (vasodilation), hypotension, reflex tachycardia, tolerance with continuous use
Nursing monitoring: BP before and after administration. Do not use with PDE-5 inhibitors (sildenafil, tadalafil) — fatal hypotension. Nitrate-free interval of 10–12 hours daily to prevent tolerance. IV nitroglycerin requires continuous BP monitoring.
Diuretics
Loop Diuretics: Furosemide (Lasix), bumetanide, torsemide
Mechanism: Block Na-K-2Cl transporter in loop of Henle → potent diuresis. Uses: Heart failure, pulmonary edema, hypertension, edema. Side effects: Hypokalemia (monitor K⁺), hypomagnesemia, hyponatremia, ototoxicity at high IV doses, dehydration. Nursing: Monitor electrolytes, BUN/creatinine, daily weight, urine output. Hold for SBP < 90.
Thiazide Diuretics: Hydrochlorothiazide (HCTZ), chlorthalidone
Mechanism: Block NaCl transport in distal tubule. Uses: Hypertension (first-line), edema. Less potent than loop diuretics — not effective in renal failure. Side effects: Hypokalemia, hyperuricemia (gout risk), hyperglycemia, hyperlipidemia. Nursing: Monitor electrolytes, glucose, uric acid levels.
Potassium-Sparing Diuretics: Spironolactone, eplerenone
Mechanism: Block aldosterone receptors in collecting duct → reduced sodium reabsorption without potassium loss. Uses: HFrEF (mortality benefit), hyperaldosteronism, edema. Side effects: Hyperkalemia, gynecomastia (spironolactone). Nursing: Monitor potassium — do not combine with ACE inhibitors/ARBs without careful monitoring.
Assessment & Monitoring
- Blood pressure and HR: Check before every cardiac medication administration. Know drug-specific hold parameters.
- Electrolytes: Potassium is critical — diuretics deplete it; potassium-sparing agents and RAAS drugs increase it.
- Renal function: BUN and creatinine affected by ACE inhibitors, ARBs, and aggressive diuresis.
- Weight and fluid balance: Daily weights for heart failure patients — trend is more important than absolute number.
- Cardiac monitoring: Beta-blockers and non-dihydropyridine CCBs require monitoring for bradycardia and AV block.
- Signs of hypotension: Dizziness, syncope, lightheadedness — especially with first doses of ACE inhibitors and after diuresis.
Nursing Considerations
- Hold beta-blockers if HR < 60 or SBP < 90 — document and notify provider per protocol
- Never abruptly stop beta-blockers — taper over days to weeks to prevent rebound tachycardia and angina
- ACE inhibitor dry cough is a class effect — patient may need to switch to ARB, not just a different ACE inhibitor
- Furosemide IV push: administer slowly (no faster than 20 mg/min) to reduce risk of ototoxicity
- Nitroglycerin sublingual for acute angina: up to 3 doses q5 minutes — if not relieved after 3 doses, call 911
- Assess for angioedema (ACE inhibitors/ARBs/ARNIs) at every assessment — can be life-threatening
- Loop diuretics cause potassium loss — supplement potassium as ordered and educate patient on dietary sources
Medication Safety
Critical Drug Interactions
- Nitrates + PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) — severe, potentially fatal hypotension. Absolute contraindication.
- ACE inhibitor + ARB — dual RAAS blockade increases hyperkalemia and renal failure risk without added benefit
- Digoxin + verapamil or diltiazem — increased digoxin toxicity (inhibit digoxin clearance)
- Beta-blocker + verapamil/diltiazem — additive bradycardia and heart block risk; avoid combination in HF
- Loop diuretic + aminoglycosides — additive ototoxicity risk
Patient Education
- Never stop cardiac medications abruptly — especially beta-blockers and antiarrhythmics. Call provider first.
- ACE inhibitor cough: This is a side effect of the medication, not an allergy. Inform provider — a switch to an ARB may be appropriate.
- Furosemide timing: Take in the morning to avoid nighttime urination. Track daily weight — report gain > 2 lb/day to provider.
- Potassium: If on a potassium-wasting diuretic, eat potassium-rich foods (bananas, oranges, potatoes) unless on a potassium-sparing drug.
- Nitroglycerin (sublingual): Keep in original glass bottle, store at room temperature away from heat and light. Replace every 6 months.
- Orthostatic hypotension: Rise slowly from lying/sitting — especially with first-dose of antihypertensives and loop diuretics.
NCLEX Pearls
- ACE inhibitor → dry cough (bradykinin). ARB → no cough. Switch if cough is intolerable.
- Beta-blockers: hold for HR < 60. Never stop abruptly — rebound hypertension and angina.
- Furosemide (loop diuretic): causes hypokalemia — monitor K⁺, supplement as ordered
- Nitroglycerin + sildenafil (Viagra) = absolute contraindication. Fatal hypotension.
- Spironolactone: potassium-sparing → hyperkalemia risk. Avoid combining with ACE inhibitors without close monitoring.
- ARNI (Entresto): must wait 36 hours after last ACE inhibitor dose before starting — risk of angioedema
- Non-dihydropyridine CCBs (diltiazem, verapamil): slow the heart rate — useful for AF rate control; avoid in decompensated HF
- Priority assessment before cardiac medications: BP and HR
Related Resources
Standards & sources
Fact-checked Jun 20, 2026This page is written to align with Institute for Safe Medication Practices (ISMP) · FDA prescribing information · The Joint Commission — National Patient Safety Goals. It is an educational summary, not a citation of any single document — always verify specific doses, values, and protocols against current guidelines and your facility policy. How we source content →
